Marico Limited reported an 89.3% reduction in Scope 1 and Scope 2 greenhouse gas (GHG) emissions intensity compared to its FY13 baseline, marking significant progress in its climate action journey.

The FMCG major also disclosed a 29.95% reduction in Scope 3 GHG emissions intensity against its FY19 baseline. These figures were highlighted on the International Day of Climate Action, underscoring the company's commitment to building a low-carbon future through strategic decarbonisation measures.

Decarbonisation drivers and energy mix

The progress achieved to date has been driven by increased renewable energy adoption, energy-efficiency measures, process optimisation and the transition to lower-carbon energy sources across operations. In FY26, renewable energy accounted for 77.3% of Marico's operational energy consumption. The company's Scope 1 and Scope 2 emissions intensity stood at 0.84 tCO2e per crore of revenue for the same period.

Strategic roadmap and targets

Marico's climate strategy is guided by its ESG 2030 Roadmap, with an ambition to achieve Net Zero emissions across Indian operations (owned manufacturing units) by 2030 and across global operations by 2040. As part of this decarbonisation roadmap, the company is targeting a 93% reduction in Scope 1 and Scope 2 emissions by 2030, compared to its FY13 baseline. Residual emissions will be addressed through carbon sequestration initiatives and verified carbon offsets.

Amit Bhasin, Chief Legal Officer, Group General Counsel and Secretary, CSR Committee of Marico Limited, stated that climate action is integral to the business strategy and long-term growth agenda. He noted that building a future-ready organisation requires sustainability to be embedded across operations, supply chains and decision-making processes.

What the numbers show

A divergence exists between the rapid deceleration of direct operational emissions and the slower pace of value chain reductions. While direct emissions intensity (Scope 1 & 2) has fallen nearly nine-tenths from the FY13 baseline, indirect value chain emissions (Scope 3) have seen a more modest decline of roughly one-third from the FY19 baseline. This suggests that while internal operational efficiencies and renewable transitions are yielding immediate results, addressing upstream and downstream carbon footprints remains a longer-term structural challenge requiring deeper supply chain collaboration.

Marico Limited has acquired an additional 24.09% equity stake in Satiya Nutraceuticals Private Limited for a cash consideration of ₹1,012.03 crore. This transaction increases Marico’s aggregate holding in the subsidiary from 60% to 84.09% on a fully diluted basis, implying a valuation of approximately ₹4,200 crore for the target entity.

The acquisition was completed on October 5, 2026, pursuant to definitive agreements entered into with the founders and certain other shareholders of Satiya Nutraceuticals. The move aligns with Marico’s strategic intent to expand its total addressable market in value-added foods and nutrition segments, as well as rapidly growing personal care and wellness categories.

Transaction details and timeline

The current tranche represents part of a broader agreement under which Marico holds rights to acquire the remaining 40% stake in Satiya Nutraceuticals. Following this acquisition, the company retains the option to purchase the residual 15.91% stake (specifically the remaining 14.09% held by founders and other shareholders) in July 2027.

The consideration for the future tranche will be determined at that time, comprising a base amount of up to ₹592 crore plus additional consideration subject to specific milestones and terms outlined in the definitive agreements. The entire transaction is structured as a cash deal, with no share swap involved.

Target entity profile

Satiya Nutraceuticals Private Limited, incorporated in February 2020 and headquartered in Mumbai, owns the brand The Plant Fix – Plix. The brand operates in the health, wellness, and personal care industry, focusing on plant-based nutrition products. The company also has a wholly owned subsidiary, Juizo Advisory Private Limited.

The acquisition is classified as a related party transaction because it involves the purchase of stakes held by the founders of Satiya Nutraceuticals and their relatives or related entities. However, Marico stated that these transactions are conducted on an arm’s length basis. The promoter group of Marico does not hold any interest in the target entity.

Financial performance of Satiya

Satiya Nutraceuticals has demonstrated significant revenue growth over the past three fiscal years. The consolidated turnover figures highlight the rapid scaling of the Plix brand within the consumer health market.

What the numbers show

The data reveals a sharp acceleration in Satiya’s top-line performance, with turnover more than doubling from FY25 to FY26. This growth trajectory supports the valuation implied by the ₹1,012.03 crore payment for a 24.09% stake, which equates to an enterprise value of roughly ₹4,200 crore for the entire entity. With Marico now holding an 84.09% majority, the financial results of Satiya will be fully consolidated into Marico’s books, directly impacting its revenue mix in the nutrition and personal care segments.